clinical

Cheryl Guttman is a medical writer based in Deerfield, Ill.

Articles

XIPERE, the first therapy utilizing the suprachoroidal space, demonstrates rapid efficacy, durable benefit, and favorable safety profile.

FDA approves XIPERE injection for treatment of uveitic macular edema

MicroPulse can reduce burden of injections for patients with diffuse diabetic macular edema.

Focal and diffuse DME: Which patients are candidates for MicroPulse?

Lynda Charters Enoch started her early “eye life” at the Schepens Eye Research Institute, Boston, which ultimately culminated in her current position as an Editor of 

Researchers set out to identify clinical and anatomic factor-associated vision loss in eyes with treatment-naïve DME and good initial VA.

Untreated DME and good baseline BCVA: Evaluating risk factors for vision loss 

John Pollack, MD, practices at Illinois Retina Associates and is an assistant professor of ophthalmology at Rush University Medical Center in Chicago. Dr. Pollack is also Chief Medical Officer at Neurotech and past President of the American Society of Retina Specialists.

John Pollack, MD, discusses gene therapy advancements in the first installment of his blog for Modern Retina.

What is encapsulated cell therapy?

A study in the United Arab Emirates reported a possible link between adverse ocular events and a COVID-19 vaccination.

COVID-19 vaccine’s impact on eyes investigated by researchers

Investigators find that wearable aid offers improved mobility.

Researchers develop collision-warning device for visually impaired patients

Videos


Javier Zarranz-Ventura MD, PhD, FEBO, discusses the key highlights from his presentation on a clinical investigation of suitable naïve versus pre-treated DME patients, and what it means for future research.

Comparing suitable naïve versus pre-treated DME patients

Dr. Jorge Calzada's diabetic macular edema blog dives into his successful treatment of DME with MicroPulse.

Using MicroPulse to reduce injections for DME

Ophthalmologists face challenges of drug delivery for retinal diseases.

The state of retina therapeutics, dissected by international panel

Key takeaways from a discussion on the management of age-related macular degeneration, diabetic macular edema, and inherited retinal disease and insight regarding what to look forward to as the field advances.

Diabetic Macular Edema